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Podocyte injury is associated with progression of many renal diseases, including diabetic nephropathy. In this study we examined
whether aldose reductase (AR), the enzyme implicated in diabetic complications in diﬀerent tissues, is modulated by high glucose
and osmolarity in podocyte cells. AR mRNA, protein expression, and activity were measured in mouse podocytes cultured in both
normal and high glucose and osmolarity for 6 hours to 5 days. Hyperosmolarity acutely stimulated AR expression and activity,
with subsequent increase of AR expression but decrease of activity. High glucose also elevated AR protein level; however, this was
not accompanied by respective enzyme activation. Furthermore, high glucose appeared to counteract the osmolarity-dependent
activation of AR. In conclusion, in podocytes AR is modulated by high glucose and increased osmolarity in a diﬀerent manner.
Posttranslational events may aﬀect AR activity independent of enzyme protein amount. Activation of AR in podocytes may be
implicated in diabetic podocytopathy.
1.Introduction
Aldose reductase (AKR1B1, EC.1.1.1.21, abbreviated as AR),
a member of the aldoketo reductase superfamily, catalyzes
thereductionofbroadspectrumofaldehydes,usingNADPH
as a cofactor. Speciﬁc AR substrates comprise saturated
and unsaturated aldehydes such as progesterone, isocorticos-
teroids, aldehydes derived from biogenc amines, methylgly-
oxal, and other harmful metabolites [1–3]. The enzyme is
distributed with varying abundance within diﬀerent tissues
[4]. The diversity of AR substrate types and its wide tissue
distribution indicates that one of the physiological roles of
AR may be detoxiﬁcation of endogenous and xenobiotic
aldehydes. Further postulated roles of this enzyme include
cell protection from oxidative and osmotic stresses [5]. The
antioxidant defense involves reduction of highly reactive
aldehydes produced by lipid peroxidation [6, 7]a sw e l la st h e
reductionofglutathioneconjugatesofunsaturatedaldehydes
[8]. The osmoprotective role of AR is associated with reduc-
tion of glucose to sorbitol whose intracellular concentration
counteracts extracellular osmotic pressure. Physiological
importance of this mechanism has been particularly well
documented in renal medullary cells in which AR activity
and protein synthesis were induced by high extracellular
NaCl concentration [9, 10].
Glucose, with its apparent Km of 50–200mM [3], is
a poor substrate for AR. Abnormally high intracellular
sugar is required to trigger aldose reductase pathway. In
consequence, glucose is converted to sorbitol and further
to fructose, with extensive NADPH consumption. Major
cytotoxic eﬀects of this pathway include oxidative stress
induced by a diminished pool of GSH, intracellular sorbitol
accumulation, and increased levels of fructose and its me-
tabolites. Finally, evidence is growing that AR may be
involved in inﬂammatory responses by aﬀecting the NF-κB-
dependent expression of cytokines and chemokines [11, 12].2 Experimental Diabetes Research
Within the kidney, the highest expression and activity of
AR is found in the medullary region. In renal cortex abun-
dance of the enzyme is very low as compared to medulla, as
well as to various other tissues [4, 13]. Nevertheless, detailed
studies have revealed the presence of AR in mesangial cells
(MCs) and in podocytes of the glomeruli [14–16]. Increased
expression of the enzyme has been demonstrated in the
glomeruli of diabetic patients [17], while both mRNA and
activity of AR were elevated in rat mesangial cells cultured in
high glucose [18].
Whereas it is accepted that aldose reductase is implicated
in pathogenesis of diabetic glomerulopathy [19–22], its role
in podocytes has not yet been investigated. Podocytes are
terminally diﬀerentiated cells, covering glomerular basement
membrane with interdigitating foot processes connected by
slit diaphragms. They play a critical role in maintaining the
glomerular ﬁlter and in producing growth factors for both
mesangialandendothelialcells.Duetotheirlimitedabilityto
proliferate and to replenish lost cells, podocyte impairment
is considered to play a central role in the development of a
majority of glomerular diseases [23]. In view of recent ﬁnd-
ings it seems likely that in diabetic patients the upregulation
of AR pathway could contribute to deleterious changes in
podocytes. The present study was designed to investigate the
eﬀect of high glucose and osmolarity, the two major factors
aﬀecting glomerular cells in diabetes, on the expression and
activity of AR in podocytes.
2.MaterialsandMethods
2.1. Cell Cultures and Experimental Protocols. Conditionally
immortalized mouse podocytes (Clone SVI, generous gift
from Dr. N. Endlich, Greifswald University, Germany) were
cultured as described previously [24]. Diﬀerentiated cells
were grown in a standard RPMI1640 medium containing
5% FBS, 100U/mL penicillin, and 0.1mg/mL streptomycin
(Sigma-Aldrich). At zero time podocytes were switched for
6, 12, 24, 48 hours, or 5 days to experimental media:
NG-Nosm (normal glucose, normal osmolarity) containing
5.5mM glucose and 285mOsm/L, NG-Hosm (normal glu-
cose, high osmolarity) containing 5.5mM glucose and
385mOsm/L, HG Nosm (high glucose, normal osmolarity)
containing 30mM glucose and 285mOsm/L, and HG-Hosm
(high glucose, high osmolarity) containing 30mM glu-
cose and 385mOsm/L. Experimental media were based on
RPMI1640 without glucose (Sigma-Aldrich) and osmolarity
was adjusted by adding mannitol. All media were supple-
mented with 5% FBS and antibiotics, as indicated above.
Osmolarity was checked using Vapor Pressure Osmometer
(VAPRO 5520, Wescor Biomedical Systems, France).
It has been shown previously that cultured human
embryonic kidney (HEK) cells rapidly utilize glucose, which
within 24 hours may result in glucose starvation, endoplas-
matic reticulum stress, and underglycosylation of numerous
proteins [25]. Therefore, using a glucometer (Accu-Chek,
RocheAppliedScience)wehaveestimatedchangesinglucose
content in the NG and HG media from podocytes cultured
for 0, 24, and 48 hours (Table 1). Based on the obtained
Table 1: Estimation of glucose content (mM) in the media from
podocytesculturedfor0,24,and48hoursinthepresenceofnormal
(NG) and high (HG) glucose. Results are expressed as means ± SE
from 5 independent measurements.
0hrs 24hrs 48hrs
NG 5.8 ±0.25 .0 ±0.44 .7 ±0.5
HG 30.0 ±0.42 7 .3 ±0.92 6 .7 ±1.3
results, 48-hour interval has been chosen for replacement of
experimental media.
2.2. Isolation and Determination of Aldose Reductase Activ-
ity. At indicated time, culture ﬂasks were placed on ice,
experimental media were discarded, and 400μL ice-cold
lysis buﬀer containing (in mM) 50 HEPES (pH 7.2), 2
DTT, 5 EDTA, and 1 tablet/10mL protease inhibitor cocktail
(Complete Mini, Roche Applied Science) was added to each
ﬂask. The cells were scrapped, transfered into eppendorf
tubes, and centrifuged at +4◦C, 14,000rpm for 30 minutes
(Eppendorf Centrifuge 5810R). Resulting supernatant was
stored at −80◦C, except for an aliquot of 25μL that was
used for immediate protein assay according to the Bradford
method [26]. Bovine serum albumin was used as a standard.
Activity of AR was determined spectrophotometrically
(Ultrospec 3000) at 37◦C as described previously [10]. In all
tested groups, steady decrease in absorbance was observed
up to 10min after reaction was started (data not shown).
Therefore, measurements were conducted for 6 minutes in
the presence and absence of D,L-glyceraldehyde to correct
for unspeciﬁc NADPH reductase activity [27]. AR activity
was normalized to protein content and expressed in mU/μg
(nmol NADPH oxidized per minute per μg protein), based
on a molar absorption coeﬃcient of 6220M−1·cm−1.
2.3. Immunoblot Analysis. Immunobloting was performed
using standard techniques. In brief, trypsynized cells were
centrifuged at 2,000 rpm for 10 minutes in +4◦C; resulting
pellet was lysed on ice in a buﬀer (pH 8.0) containing 1%
Nonidet P-40, 20mM Tris, 140mM NaCl, 2mM EDTA, 10%
glycerol, and protease inhibitor cocktail (Complete Mini,
Roche Applied Science) and centrifuged for 20 minutes at
14,000rpm in +4◦C. Fifteen micrograms of total protein
were subjected to SDS-PAGE and transfer electrophoresis.
The proteins on PVDF Immobilion membranes (Millipore,
Bedford, MA, USA) were probed with primary antibodies
to AR (1:400, rabbit polyclonal, Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA) and to α-smooth muscle actin
(1:2000, mouse monoclonal, Sigma-Aldrich, St. Louis, MO,
USA) followed by alkaline phosphatase-labeled secondary
antibodies (goat anti-rabbit IgG and goat anti-mouse IgG,
Santa Cruz Biotechnology Inc). The complexes were visu-
alisedwith5-bromo-chloro-3-indolyl phosphate(BCIP)and
nitro blue tetrazolium (NBT; Sigma-Aldrich) and pho-
tographed in UVP BioImaging GDS-8000 system (UVP Inc.,
Upland, CA), using LabWorks 4.0 Image Acquisition and
Analysis Software.Experimental Diabetes Research 3
Table 2: PCR conditions for aldose reductase and β-actin genes. Previously published primer sequences were veriﬁed by NCBI BLAST.
Ampliﬁcation was conducted for 26 cycles.
Gene Sequence of primers (5  to 3 ) Amplicon (bp) Annealing temp. (◦C)
Aldose reductase Sense: CCCAGGTGTACCAGAATGAGA 580 53.1
Antisense: TGGCTGCAATTGCTTTGATCC
β-actin Sense: CCGTAAAGACCTCTATGCCA 299 50.8
Antisense: AAGAAAGGGTGTAAAACGCA
2.4. RNA Isolation and Reverse Transcription-Polymerase
C h a i nR e a c t i o n( R T - P C R ) .Total RNA was extracted from
each culture sample using TRI Reagent (Sigma-Aldrich)
according to the manufacturer’s instructions. RNA purity
and concentration were determined by measuring the opti-
cal densities at 260nm and 280nm. Two micrograms of
RNA were reverse transcribed at 37◦C for 60min using
0.1μM antisense primer, 5U/μL MuLV reverse transcriptase
(Promega, Madison, WI, USA ), 0.5mM deoxynucleotide
triphosphate mixture (dNTP), and 1U/μL RNase inhibitor
(Sigma-Aldrich). The PCR step was performed using 2.5U
Maxima Hot Start Taq DNA Polymerase (Fermentas Int
Inc.), with 20μLR Tp r o d u c ta n d8 0μL PCR mix containing
0.1μM sense primer. Primer sequences and PCR ampliﬁca-
tion conditions are shown in Table 2. Controls containing
water in place of RNA were included in all experiments and
gave negative results. The PCR products (18μL/lane) were
resolved on ethidium bromide-stained 1.4% agarose gels,
viewed and photographed on a UV transilluminator (UVP
Inc., Upland, CA).
2.5. Densitometry. Semiquantitative analysis of the band
opticaldensitieswasperformedusingQuantityOnesoftware
(Bio-Rad, Hercules, CA, USA) and normalized to β-actin
(RT-PCR) or to α-smoth muscle actin (immunobloting).
2.6. Flow Cytometry. Following incubations, the cells were
washed with PBS, trypsinized, suspended in PBS, and
centrifuged two times for 7 minutes at 400 × ga tr o o m
temperature. The pellets were then resuspended in 1mL of
a cold permeabilizing buﬀer (Ebioscience, USA), incubated
for30minutesinroomtemperature,centrifugedandwashed
with 1mL washing buﬀer (WB) (Ebioscience, USA ). Finally,
1.5 × 105 cells/tube were stained for 60 minutes at room
temperature with 1:100-diluted rabbit antibodies to AR
(Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA).
Antigen-bound antibodies were visualized by 40 minutes
incubation with 1:100 diluted Alexa488-conjugated don-
key anti-rabbit IgG (Molecular Probes, Eugene,OR, USA).
Stained cells were washed with 1mL WB, resuspended
in 500μL PBS and analyzed in ﬂow cytometer (Canto II
Flow Cytometer, BD, USA). Basing on measurements of the
single-cell ﬂuorescence intensities, arbitrary selection of AR-
positive cells was performed. For each selected population,
the mean ﬂuorescence index (MFI) was determined using
FACS Diva software (BD, USA). Negative controls displayed
negligible ﬂuorescence of permeabilized podocytes.
2.7. Immunocytochemistry. For immunocytochemical anal-
ysis, the podocytes were grown on collagen-coated round
glass cover slips in 24-well culture plates containing exper-
imental media, as indicated before. Immunocytochemistry
was performed as described previously [28]. Brieﬂy, the cells
were ﬁxed (2% paraformaldehyde), permeabilized (0.3%
Triton X-100), and incubated in blocking solution (2%
fetal bovine serum, 2% bovine serum albumin, 0.2% ﬁsh
gelatine, in PBS) for 60 minutes. This was followed by
incubations, 60min with primary rabbit antibody to AR
(1:100, Santa Cruz Biotechnology, Inc.) and 45min with
secondary anti-rabbit IgG conjugated with Cy3 (1:200,
Rockland Immunochemicals Inc Gilbertsville, PA, USA).
Nonspeciﬁc staining was controlled by replacing primary
antibody with blocking solution alone. F-actin was stained
using 1:200 Alexa 488-phalloidin conjugate (Molecular
Probes, Eugene, OR, USA). Apoptotic nuclei were detected
by DNA condensation, using 1μg/mL 4 ,6-diamidino-2-
phenylindole dihydrochloride (DAPI, Merck Chemicals). All
antibodies and stains were diluted in blocking solution. The
cover slips were mounted on microscope slides using 15%
Mowiol solution (Calbiochem, La Jolla, CA), and stained
cellswereanalyzedunderﬂuorescencemicroscope(Olympus
IX51), using cellSens v.1.3 imaging software (Olympus).
2.8. Statistical Analysis. All of the data are presented as
means ± SEM from 3 to 5 independent experiments. The
statistical analyses were performed using SigmaStat (version
3.0. for Windows; SPSS Inc., Chicago, IL, USA). Data were
analysed using Student’s t-test for comparisons. Statistical
signiﬁcance is indicated by P<0.05.
3. Results
3.1. Time Course of AR Activity in Podocytes. In NG-Nosm
cells, AR activity remained constant during the whole incu-
bation time (Figure 1). In contrast, hyperosmolar conditions
stimulated the activity of AR in NG cells reaching peak level
(0.213 ± 0.004 versus 0.117 ± 0.004mU/μg in NG-Nosm,
P<0.05) already after 6 hours of incubation. Thereafter,
a gradual decrease was observed, reaching the Nosm level
after 48 hours. On the other hand, in HG medium after
6 hours only slight increase of AR activity was observed.
After 5 days it reached the level that was only 1.2-fold higher
than in the NG-Nosm group. Time course of changes in
enzyme activities was similar in HG podocytes from both,
normo- and hyperosmolar media which suggests that high4 Experimental Diabetes Research
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Figure 1: Time course of the changes in podocytic aldose reductase
(AR) activity. Podocytes were cultured for indicated time periods
in media with normal (5.6mM, NG) or high (30mM, HG)
glucose content, and/or normal (285, Nosm) or high (385, Hosm)
osmolarity. Cell lysates were prepared as indicated in Materials
and Methods. Enzyme activities were calculated from the rate of
the decrease in NADPH absorbance and are shown as absolute
values. Data are expressed as means ± SE from 3–5 independent
experiments, ∗P<0.05 versus NG-Nosm cells.
glucose counteracted the stimulatory eﬀect elicited by high
osmolarity in NG cells.
3.2. Eﬀect of Increased Osmolarity on AR Protein Expression
and Activity. Semiquantitative immunoblot analyses of the
cells at each incubation time were performed to check
whether observed changes in AR activity were related
to changes in enzyme protein expression. The eﬀects of
short-time (6 hours) and prolonged (5 days) exposition
to experimental conditions were further checked by ﬂow
cytometry. Densitometric quantiﬁcation of obtained 37kDa
bands revealed that in hyperosmolar conditions, after 6-
hour incubation AR expression in NG podocytes was
markedly elevated (by 70 ± 13%, P<0.05 versus NG-
Nosm) (Figure 2(a)). Quantitative ﬂow cytometric analysis
(Figure 2(c)) yielded similar results, showing that AR
increased by 86 ± 2% (P<0.01). Respectively, activity of
the enzyme increased by 82 ± 2%, P<0.05 as compared to
theNG-Nosmcells(Figure 2(b)).However,whileARprotein
expression in NG-Hosm cells remained increased during
entire time activity of the enzyme dropped to the basal
level after 24 hours. Conversely, no signiﬁcant changes in
expression or activity of AR were observed in HG podocytes
exposed to increased osmolarity.
Immunoﬂuorescent staining after 5 days of incuba-
tion conﬁrmed that expression of AR in cytosol of NG-
Hosm podocytes was upregulated, as compared to NG-
Nosm and HG-Hosm cells (Figure 3(b)). NG-Nosm cells
expressed evident perinuclear pools of AR with relatively
weak staining in the rest of cytosolic regions (Figure 3(a)).
In NG-Hosm podocytes, AR strongly stained in a diﬀuse
pattern throughout the cell body. High osmolarity had no
apparent eﬀect on the F-actin cytoskeleton in NG cells.
However, NG-Hosm podocytes displayed more delicate
stress ﬁbers, which was particularly noticeable after 5 days
of incubation (Figure 3(d)).
3.3. Eﬀect of Glucose Concentration on AR Protein Expression
and Activity. In podocytes cultured in HG-Nosm media, AR
proteinwasmarkedlyincreased(by37±4%,P<0.025versus
NG-Nosm) as early as 6 hours after shifting to high glucose
(Figures 4(a) and 4(c)). The enzyme remained elevated
during the whole incubation period. However, this increase
was not accompanied by signiﬁcant changes in enzyme
activity (Figure 4(b)). Conversely, in podocytes cultured in
HG- Hosm media, high glucose suppressed the expression
of AR and this eﬀect could be observed over the whole
period of incubation. After 5 days, AR protein decreased by
55 ± 15%, P<0.05 as compared to NG-Hosm cells. During
theﬁrst12hoursofincubationinHG,activityofARwasalso
suppressed (by 26 ± 2%, P<0.05 versus NG-Hosm at 6h),
while longer incubation seemed to reverse this eﬀect.
3.4. Expression of AR mRNA in Podocytes. To verify whether
the changes in enzyme protein expression reﬂect the mRNA
levels for AR, we have reverse transcribed the total RNA
from all experimental groups. Results of RT-PCR analysis
revealed that already in basal (normal glucose and osmolar-
ity) conditions, the expression of AR mRNA in podocytes
was relatively high, with abundance comparable to that of
glyceraldehyde-3-phosphate dehydrogenase (GAPDH, data
not shown) and β-actin (Figure 5(c)). Since high ambient
glucose concentration may aﬀect the expression of GAPDH
[29], for our further analyses we have used β-actin as a
housekeeping gene. Comparison of optical density ratios
(AR to actin) of respective immunoblots to the RT-PCR
products showed that expressions of AR mRNA and protein
were correspondingly modulated. Similar to the enzyme
activityinNG-Nosmcells,ARmRNAandproteinexpression
remained at a constant level up to 5 days of incubation.
Enhanced (NG-Hosm and HG-Nosm cells) or suppressed
(HG-Hosm cells) expression of AR protein (Figure 5(b))
was accompanied by respective changes in mRNA levels
(Figure 5(d)). This may suggest that in our experimental
conditions, transcription and translation processes were
synchronized, while modulations of AR activity might be
ascribed to posttranslational modiﬁcations of the enzyme.
4. Discussion
In the present study we show that in cultured mouse
podocytes, expression and activity of aldose reductase (AR)
are modulated by high glucose and hyperosmolarity in a
diﬀerent manner. High osmolarity alone induced a rapid
but transient increase of AR activity (Figures 1,a n d2(b)),
while only slight activation of the enzyme by high glucose
was observed. As compared to the NG-Hosm cells from
respective incubation time points, during the ﬁrst 12 hoursExperimental Diabetes Research 5
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Figure 2: Eﬀect of high osmolarity on (a, c) protein expression and (b) activity of AR in podocytes cultured in normal (NG) and high (HG)
glucose. Protein expression was quantiﬁed by densitometry of immunoblot bands (a) and by ﬂow cytometry (c) as indicated in Materials
and Methods. Data are shown as percent changes of respective normoosmolar (Nosm) control values at the indicated time points (a, b) or as
a mean ﬂuorescence index, MFI (c). Results are expressed as means ± SE from 3–5 independent experiments, ∗P<0.05, ∗∗P<0.01 versus
Nosm cells from respective groups.
of incubation activity of AR was even suppressed by
high glucose (Figure 4(b)) with parallel decline in protein
expression (Figures 4(a) and 4(c)). In a variety of cells,
hyperglycemic conditions have been reported to upregulate
aldose reductase activity both in vivo and in vitro [2, 30, 31].
A p a r tf r o mn u m e r o u sd e l e t e r i o u se ﬀects associated with its
activation [5], the beneﬁcial roles ascribed to AR include
protection of the cells against glucose-derived osmotic [32]
andoxidative[33,34]stresses.Nevertheless,similartoresults
observed in our study, reduction of AR protein has been
reported in mouse podocytes cultured in hyperosmolar HG
medium for two weeks [35] and in arterial endothelium
[36]. In turn, high glucose-induced loss of AR activity
was found in epithelium from thick ascending limb of
Henle’s loop [37]. In our experiments, high glucose not
only counteracted the activation of AR in HG-Hosm cells
but also blunted the AR activity in HG-Nosm podocytes,
despite upregulated enzyme protein (Figures 1, 4(a),a n d
4(c)). The mechanism underlying this paradoxical eﬀect is
not clear. It could be possible that AR activity wassuppressed
in response to intracellular sorbitol accumulation. However,
while some authors have observed such suppression [9],
others state that this enzyme does not exhibit feedback
inhibition [38]. Another possibility is that glucose-induced
cytotoxicity [39] that was observed in podocytes in vivo
and in vitro [40] accounted for the drop in measured AR
activity. In our experiments, however, nuclear DAPI staining
did not reveal any signs of apoptosis in either of tested
cell groups. It is also possible that in high glucose milieu
the enzyme was aﬀected by posttranslational modiﬁcations.6 Experimental Diabetes Research
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Figure 3: In podocytes cultured in normal glucose (NG), 5-day exposition to hyperosmolar conditions (Hosm) noticeably increased and
redistributed AR immunostaining (b), as compared to the cells from normoosmolar (NG-Nosm) (a) or high glucose (HG-Hosm) (c)
conditions. In the NG-Nosm cells, immunoreactivity was localized predominantly in perinuclear regions (arrows), while in NG-Hosm cells,
intensive staining was diﬀuse throughout the cytoplasm (arrows). HG-Hosm cells stained to AR in a diﬀuse manner, with less pronounced
perinuclear regions as compared to NG-Nosm. In response to high osmolarity, rearrangements of F-actin cytoskeleton were observed in NG
cells. Thick transcellular stress ﬁbers observed in NG-Nosm cells (d) were replaced by thin, more delicate F-actin ﬁlaments (e). Nonspeciﬁc
staining control (f) was prepared as described in Materials and Methods. Magniﬁcation ×400 (a–c, f) and ×200 (d, e).
One of the major molecular mechanisms implicated in
hyperglycemia cell damage is induction of protein kinase
C (PKC) isoforms [41]. Multiple interrelationships between
PKCandARhavebeendescribed,includingphosphorylation
and translocation of AR to the mitochondria [42]. In high
glucose milieu, PKC mediates also activation of NF-κB,
which, in turn, can regulate the transcription of AR gene
[43]. Since PKC isoforms have been found in podocytes
[44, 45], this mechanism could also be responsible for
increased AR expression in HG-Nosm cells. On the other
hand, enzymatic activity of AR is redox-sensitive due to
the presence of cysteine residue (Cys-298) near the active
site [46]. Both oxidation and S-thiolation of this residue
modulate kinetics and activity of the enzyme [5, 47, 48].
It is therefore possible that high glucose-induced oxidative
stress in podocytes [49, 50] could perturb the intracellular
redox status leading to suppression of AR. Posttranslational
modiﬁcations of AR may also involve an interplay between
activatory S-nitrosylation of Cys-298 by nitric oxide (NO)
and inhibitory glutathiolation of S-nitrosylated AR [51].
In addition, exposition to high glucose has been shown to
inhibit NO synthesis in vivo and in vitro [52, 53]. Therefore,
depletionofbioavailableNOcouldbeanotherreasonforloss
of AR activity in podocytes incubated in HG medium. It has
been reported previously that podocytes express neuronal
[54] as well as inducible [55] forms of nitric oxide synthases;
therefore such autocrine/paracrine regulation of AR by NO
cannot be excluded.
In contrast to high glucose, hyperosmolarity appeared to
markedly stimulate AR activity in NG podocytes (Figures 1
and 2(b)). This was not surprising, as osmotic stress is
considered to be a major regulator of AR expression, and
aldose reductase is called “a hypertonicity stress protein”
[56]. In the sequences of rat and human AR promoter
regions, osmotic response element (ORE) sequences have
been found [57, 58], and induction of aldose reductase in
response to increased osmolarity was reported in numerous
renal and nonrenal cells [10, 15, 59, 60]. Moreover, similar
to podocytes, in renal tubular epithelium and in Schwann
cells induction of AR occurred in response to osmotic
stress but not to high glucose per se [61, 62]. However, in
our experiments, the eﬀect seemed to be relatively short-
lived. Although AR protein increased with duration of
incubation in the Hosm conditions (Figure 2), activity of the
enzyme declined simultaneously. While positive correlation
between AR expression and activity was observed in some
cell types [62, 63], the discrepancies were found in other
[64, 65] which suggests that activation of the enzyme by
exogenous factors could play a role independent of protein
level. There are two forms of native AR, one of them
reduced (not active) and the other one oxidized (active)
[66–69]. Since mannitol is known to exert antioxidant
properties, prolonged incubation of podocytes in mannitol-
containing hyperosmolar medium might favour the reduced
form of the enzyme. It is also tempting to speculate that
hyperosmolarity-induced intracellular glutathione depletionExperimental Diabetes Research 7
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Figure 4: Eﬀect of high glucose on (a, c) protein expression and (b) activity of AR in podocytes cultured in normo- (Nosm) and high-
(Hosm) osmotic medium. Protein expression was quantiﬁed by densitometry of immunoblot bands (a) and by ﬂow cytometry (c) as
indicated in Materials and Methods. Data are shown as percent changes of respective normoglycemic (NG) control values at the indicated
time points (a, b) or as a mean ﬂuorescence index, MFI (c). Results are expressed as means ± SE from 3–5 independent experiments,
∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001 versus NG cells from respective groups.
could stimulate a transmembrane cystine transport into
the podocytes. Uptake of L-cystine in order to replenish
intracellular glutathione levels has been shown in various
cells and organs, including the kidney [70, 71]. However,
cystine, by binding to Cys-298, could also directly inactivate
aldose reductase [72]. Transmembrane cystine transport
occurs either via glutamate transporters (Na+-dependent
transport) or by glutamate/cystine antiporters [71] that are
particularly abundant in brain tissue. By now, none of
these transporters were found in podocytes. Nevertheless,
podocytes have been shown to possess a diﬀerentiated amino
acid transport system [73] including vesicular glutamate
transporter [74, 75], and recent ﬁndings reveal more and
more similarities between podocytes and neuronal cells. It
seems therefore plausible that glutamate-dependent cystine
transport may also be present in podocytes. However, this
concept has not been proven yet.
Relatively high basal AR mRNA expression (Figure 5(c))
may suggest that podocytes are well equipped to metabolize
not only toxic aldehydes formed inside the cells but also
diverse plasma-derived endogenous and xenobiotic aldehy-
des that may cross the cell membrane during ﬁltration pro-
cess.ProminentexpressionofARproteinhasbeenpreviously
observed in rat and ox podocytes [76, 77]. Such constitutive
expression of the enzyme may allow the podocytes to
quickly adjust their AR system accordingly to current solute
composition and/or osmolarity. However, in hyperglycemia,
modulation of AR expression and activity may contribute8 Experimental Diabetes Research
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Figure 5: Expression of AR protein (a, b) and mRNA (c, d) in podocytes cultured in experimental media for 6 hours and 5 days, as described
in Materials and Methods. (a) 15μg protein from cell lysates was immunoblotted using rabbit polyclonal anti-AR antibody and visualized
with BCIP-NDT, yielding ∼37kDa bands for AR and ∼47kDa bands for α-smooth muscle actin. (b) Results of densitometric quantiﬁcation
of corresponding immunoblot bands are expressed as optical density (OD) ratios of AR to actin bands. (c) 2μg total RNA was reverse
transcribed and resulting cDNAs were ampliﬁed in 26 cycles, using speciﬁc primers for AR and for β-actin (see Table 2). 18μLo fP C R
products were electrophoresized in 1.4% agarose gel and stained with ethidium bromide. (d) Results of densitometric quantiﬁcation of
corresponding RT-PCR products are expressed as optical density (OD) ratios of AR to actin bands. ∗P<0.05 versus NG-Nosm, ∗∗P<0.05
versus NG-Nosm and HG-Nosm 5-d, ∗∗∗P<0.025 versus NG-Nosm and HG-Hosm 6h. a.u., arbitrary units.
to the pathogenesis of glomerular impairment. In dia-
betes, increased plasma glucose results in elevated plasma
osmolality. According to our HG-Hosm results, activity of
podocytic AR may be then suppressed, which could impair
antiosmotic defence and lead to podocyte loss. On the other
hand, increased AR protein expressed by the podocytes
appeared to be one of the major antigens in patients
with membranous nephropathy [16]. Therefore, osmolality-
dependent elevation of AR protein in podocytes may trigger
the inﬂammatory response within the glomerulus. Aldose
reductase has also been shown to modulate production
of cytokines such as tumor necrosis factor α (TNF α)o r
vascular endothelial growth factor (VEGF) in the kidney and
vascular smooth muscle cells [5, 21, 48, 78]. In glomeruli,
podocytes are a prominent source of VEGF [79], TNF α
[80], as well as of other cytokines. Their expression not only
contributes to the podocyte integrity and survival but also
regulates the functions of other glomerular and tubular cells.
It seems likely that in diabetic conditions, modulation of
AR in podocytes may be essential for production of factors
responsible for regulation of glomerular barrier structure
and permeability. Additionally, nonimmune eﬀects of AR
should be considered, such as oxidative damage, sorbitol
accumulation, or overproduction of fructose [5, 48].
In summary, these results show that in cultured
podocytes aldose reductase is regulated by both high glucoseExperimental Diabetes Research 9
and high osmolarity. Furthermore, changes in AR protein
expressed by the cells do not necessarily correspond to
changes in activity of the enzyme. High glucose alone
elevated AR protein level, which was not accompanied
by respective enzyme activation. High osmolarity in turn
stimulated both activity and expression of AR in podocytes
already within the ﬁrst hours of exposition. However, while
AR protein remained increased over the whole time of incu-
bation, the activity of the enzyme concomitantly decreased.
This suggests that in podocytes posttranslational events
may aﬀect AR activity independent of the enzyme protein
content. Modulation of AR-dependent metabolic pathway
in podocytes may be implicated in the pathomechanisms of
diabetic podocytopathy.
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